De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2023 gaat kunt u via de nummers vooraf aan de titels van de abstracten deze vinden.
Te beginnen met die van Sara M. Tolaney, MD, MPH
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session
Breast Cancer, Early Stage
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. N Harbeck
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study. P Schmid
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. L Gianni
LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). S Loi
LBA21 KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. F Cardoso
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
377O A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. S Hurvitz
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
380MO
SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial.
Y Yin
Monday, October 23, 2023
10:15–11:45 CEST; Mini Oral Session
LBA23
Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC).
A Bardia
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
LBA11
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial. A. Bardia
Abstracten aanbevolen door Prof. Lillie Shockney
Friday, October 20, 2023
16:00–17:20 CEST; Proffered Paper Session
Supportive and Palliative Care
2030O Remote symptom monitoring with electronic patient-reported outcomes (ePROs) during treatment for metastatic cancer: Results from the PRO-TECT trial (Alliance AFT-39). E Basch
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
Breast Cancer, Metastatic
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
378O Persistence under abemaciclib and endocrine treatment (ABA+ET) in patients with advanced breast cancer (aBC) – first results of the randomized IMPACT Trial comparing patient coaching with the MASCC Oral Agent Teaching Tool (MOATT) versus local routine patient coaching (LC). MK Welslau
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
Breast Cancer, Metastatic
379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase 1b/2 study. P Schmid
380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial. Y Yin
382MO Updated results from the phase 1/2 study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD ) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. NU Lin
384MO Final overall survival analysis for fulvestrant vs anastrozole in endocrine therapy (ET)-naïve, hormone receptor-positive (HR+) advanced breast cancer (FALCON). J Robertson
387MO First Results of the SOLTI-1903 HOPE's Patient-Centric Molecular Screening Program in Advanced Breast Cancer. T Pascual
Abstracten aanbevolen door Dr. Ben Anderson:
Saturday, October 21, 2023
11:15–11:45 CEST; EONS Session
Health Promotion, Prevention, and Screening
Promoting cancer screening among under-represented populations. SM Symmons
Saturday, October 21, 2023
12:00–13:30 CEST; EONS Industry Satellite Symposium
MSD – Improving Health Literacy Across the Patient Pathway From Screening and Prevention to Treatment and Care
Cancer nursing's potential to address the growing cancer burden in Europe. D Protogiros
Exploring the conceptual underpinnings of cancer literacy and how it guides policy and action. K Sorensen
Role of cancer nurses in cancer screening and prevention. L Benito
Sunday, October 22, 2023
11:15–11:45 CEST; Special Session
More Intelligent Trial Design
Trials in low-and middle-income countries (LMIC). CS Pramesh
Monday, October 23, 2023
11:15–11:45 CEST; Mini Oral Session
Breast Cancer, Early Stage
LBA22 Connected device and therapeutic patient education to promote physical activity among in women with localized breast cancer: results from the DISCO randomized trial. B Fervers
239MO Impact of body mass index and its change on survival outcomes in patients with early breast cancer: A pooled analysis of individual-level data from BCIRG-001 and BCIRG-005 trials. H Chen
240MO Prognostic and predictive impact of estrogen/progesterone receptor (ER/PR), and Ki-67 expression: An exploratory analysis from the monarchE trial in patients with high-risk, HR+, HER2-, early breast cancer (EBC). MP Goetz
243MO Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial. HM Kuerer
Policy and Preventive Strategies
1759MO Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study. L Kassem
Aanbevolen abstracten door Dr. Reshma Mahtani:
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session
Breast Cancer, Early Stage
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. N Harbeck
LBA21 KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. F Cardoso
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
Breast Cancer, Metastatic
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
Saturday, October 21, 2023
Posters
Breast Cancer, Metastatic
389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC). J Cortés
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
Breast Cancer, Metastatic
382MO - Updated results from the phase I/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer. NU Lin
Monday, October 23, 2023
16:30–18:00 CEST; Mini Oral Session
Breast Cancer, Early Stage
LBA23 Invasive disease–free survival (iDFS) across key subgroups from the Phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC). A Bardia
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial. A Bardia
Aanbevolen abstracten door Dr. Lee Schwartzberg:
Friday, October 20, 2023
14:00–15:40 CEST; Proffered Paper Session
Breast Cancer, Early Stage
LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. N Harbeck
LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study. P Schmid
LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. L Gianni
LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). S Loi
LBA21 KEYNOTE-756: Phase 3 study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. F Cardoso
Saturday, October 21, 2023
10:15–11:35 CEST; Proffered Paper Session
Breast Cancer, Metastatic
376O Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase 3 DESTINY-Breast04 study. S Modi
377O A Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) in Patients (pts) With HER2-Positive (HER2+) Metastatic Breast Cancer (mBC) With Brain Metastases (BMs) from DESTINY-Breast (DB) -01, -02, and -03. S Hurvitz
Sunday, October 22, 2023
8:30–9:55 CEST; Mini Oral Session
Breast Cancer, Metastatic
380MO SKB264 (MK-2870) in previously treated hormone receptor-positive (HR+)/ HER2-negative metastatic breast cancer (mBC): results from a phase I/II, single-arm, basket trial. Y Yin
383MO Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study. K Jhaveri
Monday, October 23, 2023
16:30–18:15 CEST; Proffered Paper Session
Presidential 3
LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised Phase 3 TROPION-Breast01 trial. A Bardia
Gerelateerde artikelen
Plaats een reactie ...
Reageer op "ESMO 2023: aanbevolen abstracten voor borstkanker door oncologen en borstkankerspecialisten"